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Lung cancer is the leading cause of cancer-related deaths worldwide [1]. In 2018, there were 2 million new cases and
1.7 million deaths attributed to lung cancer [1]. Histopathological subtypes of lung cancer include non-small-cell
lung cancer (NSCLC) and small-cell lung cancer (SCLC). NSCLC accounts for approximately 85% of lung cancer
cases, which can be further divided into adenocarcinoma accounting for 38.5%, squamous cell carcinoma for nearly
20% and bronchoalveolar and large cell carcinomas accounting for the rest [2]. SCLC arises from neuroendocrine
cells of bronchus and constitutes approximately 15% of cases [3].
Lung cancer is typically a lethal malignancy, primarily due to delay in definitive clinical diagnosis and con-
sequently has a poor prognosis [1]. Thus, there is an urgent need for novel and efficacious diagnosis, as well as
therapeutic options. The research in this area could be accelerated by utilizing short-term animal models that
recapitulate the hallmark features of lung cancer that will be valuable in pinpointing novel therapeutic targets
and appropriate interventions [4]. Importantly, cigarette smoking (both active and passive) is a major contributing
factor for the development of lung cancer and chronic obstructive pulmonary disease [5]. It is likely that increasing
air pollution, especially in low- and middle-income countries, is also likely to contribute to lung cancer devel-
opment [6]. However, the precise underlying mechanisms that drive carcinogenesis, both molecular and cellular,
remain poorly understood [4,7]. Recent advances in genetic engineering technology, including transposon-based
insertional mutagenesis, RNA interference and engineered nucleases, as well as chemically-induced preclinical
animal models of lung cancer have significantly contributed to furthering our understanding of carcinogenesis and
associated pathophysiology. In this commentary, we will specifically focus on the recent advances in animal models
of lung cancer.
Genetically modified animal models of lung cancer
Highly specific transgenic mouse models that closely resemble the genetic and pathophysiological features of
human lung cancers are now available. Tumor suppressor genes (TSGs), which play a vital role in lung cancer, are
often deleted or mutated to induce lung cancer development in mice. Based on the genome database and known
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mutations, Wu et al. selected 55 TSGs and screened them for their roles in tumorigenesis using the somatic gene
editing technique, clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) in the KrasG12D/+
(Kirsten rat sarcoma viral oncogene homolog) mouse model of lung cancer [8]. Interestingly, of the genes Utx,
Ptip, Acp5, Acacb and Clu, only when the Utx gene was deleted, tumor progression increased [8]. Consequently,
the study of specific TSGs may facilitate our understanding of lung tumorigenesis and investigation of novel
pharmacotherapies. Lung cancer patients with a history of cigarette smoking can exhibit a deletion in the small
arm of chromosome 3p21.3, which has several tumor suppressor genes such as LIMD [9]. In a study by Jamsai
et al. the gene-trapped embryonic stem cell line was used to generate Rbm5 deficient (−/−) mice. When treated
with the cigarette carcinogen NNK (4-[Methyl(nitroso)amino]-1-(3-pyridinyl)-1-butanone), these mice developed
more aggressive cancers compared with wild-type mice with an increased number of adenocarcinoma nodules.
Evidently, Rbm5 acts as a tumor suppressor gene in cigarette smokers [10].
Elucidating the role of the protumor microenvironment and hallmark immune signatures is essential in de-
veloping novel therapies for lung cancer. To study the role of the protumor microenvironment in lung cancer,
Faget et al. used Kras and p53 (KP) driven lung adenocarcinoma mice crossed with Rag1 gene to demonstrate
that Gr1+ neutrophil deletion leads to enhanced tumor growth and reduced the efficacy of programmed cell
death-1 immunotherapy [11]. They also showed that increased angiogenesis was associated with neutrophils, which
promote hypoxia and Snail production that in turn causes tumor progression [11]. The use of cell-free DNA and
circulating tumor DNA is gaining attention as promising biomarkers for lung cancer. This coupled with the use
of Cre-regulated genetically modified mice such as KrasLox-G12D, KrasLSL-G12D and KrasWT and using techniques like
micro-computed tomography and droplet digital PCR assay, facilitates the detection of pre-malignancy of lung ade-
nocarcinoma, which can be a promising diagnostic tool [12]. Conditional triple deficient Rb/p53/p130flox/flox mice
that develop SCLC with Hes1 transcriptional factor showed that the tumors had notch-active protumorigenic
(non-neuroendocrine) cells that were generated from neuroendocrine cells. Inhibition of transcriptional repressor
REST in notch signalling prevented cell differentiation in SCLC. Thus, notch inhibitors along with chemotherapy
may be an effective therapy for SCLC [13].
The role of lung microbiota in communication between bacteria and inflammation is gaining attention. Jin
et al. showed an interesting correlation between microbiota, inflammation and lung adenocarcinoma [14]. In KP
mice it was observed that microbiota promote adenocarcinoma with increased cytokine expression via promotion
of Vγ6+ Vδ1+ T(γδ T) cells. Thus, alteration in the pathway of microbiota mediated γδ T cell activation and
proliferation offers it as a therapeutic target [14]. Furthermore, kinases were reported to be tumor markers, including
proto-oncogene ROS1-receptor tyrosine kinase 1 – which has an important role in NSCLC progression [15]. Notably,
Arai et al. developed an EZR-ROS1 transgenic mouse model to study the role of the EZR-ROS1 fusion gene [15]. The
authors first fused the EZR and ROS1 genes via the expression of a fusion kinase in NIH3T3 cells, and then injected
these cells into nude mice, which resulted in the rapid development of early stage multiple adenocarcinomas. This
new model can be used to study therapeutic agents for patients expressing ROS1 rearrangements [15].
The majority of mutations occurring in lung cancer models are Kras dependent, and corresponding mutated
mice are widely used models in preclinical studies [16]. One profiling study on exomes and transcriptomes of Kras
mutations in genetically modified mouse models suggested that a greater degree of heterogenicity evolved during
tumorigenesis [17]. This indicates the need for further refinement of genetically modified animal models, which
would aid more effective development of therapeutics.
Chemically induced animal models of lung cancer
Chemically induced animal models of lung cancer are increasing in importance compared with xenograft and
genetically modified models due to their ease of application, rapid timeframes and efficiency in reproducibility.
Recently, these models have gained attention, primarily due to major increases in the number of lung cancer cases
related to cigarette smoking and other environmental carcinogens, such as polycyclic aromatic hydrocarbons and
aromatic amines [18]. The major chemical carcinogens in cigarette smoke include NNK and polycyclic aromatic
hydrocarbons [19]. These carcinogens have been extensively used to develop different models of lung cancer. For
instance, NNK is used to induce adenocarcinoma [20] whereas N-nitroso-tris-chloroethylurea (NTCU) promotes
the development of squamous cell carcinoma [21]. Merval et al. developed a novel animal model of NSCLC by
inducing adenocarcinoma using diethylnitrosamine in the FVB/N (Friend leukemia virus B) mouse strain [22].
Interestingly, no mutations in the hot spot areas of EGFR and Kras genes were observed, which highlights the
importance of this particular model in investigating the pathogenesis of EGFR and Kras negative tumors [22].
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Lung epithelial cell lines such as BEAS-2B and human bronchial epithelial cells that lack p53 expression when
exposed to NNK exhibited activation of IGF-1R phosphorylation via β-adrenergic receptor (β-AR) [23]. Blocking
β-AR with NNK antagonists in A/J mice with lung cancer suggests that blockade of β-AR may be an effective
therapy for lung cancer [23]. In addition to NNK, inorganic phosphate (Pi) also plays a crucial role in signal
transduction and expression of several genes like transcription factor Nrf2 during cell division [24]. However, the
role of Pi in lung cancer pathogenesis is poorly understood. A study investigating the role of high phosphate diet
for 1, 2 and 4 months in Kras mice suggested that the diet enhanced autophagy and epithelial to mesenchymal
transition in early and later stages due to cellular metabolic adaptation, resulting in the decline of cancer. Overall,
it is necessary to avoid high phosphate diet with early stages of lung cancer [24]. Another hallmark feature of lung
cancer is chronic inflammation, Kim et al. proposed that cigarette smoke exposure to C57BL/6J and IL-17a−/−
in mice lungs causes increased Th17 differentiation with enhanced pro-Th17 and neutrophils, by analyzing blood
and spleen, it was found that there was a systemic inflammation, eventually leading to intestinal inflammation [25].
The development of preclinical nonrodent lung cancer models may be crucial for the study of lung carcinogenesis
that may more precisely mimic the human disease. Administration of NNK to ferrets (50 mg/kg body weight) for 4
months, followed by a rest periods of 24, 26 and 32 weeks resulted in preneoplastic and neoplastic lesions [26]. This
led to the development of tumors with higher numbers of macrophages and increased expression of α7 nicotinic
acetylcholine receptors, which replicates observations in humans. Thus, non-rodent models could be used to study
the progression of lung cancer in conjunction with laboratory rodents [26]. In addition to carcinogens, genetically
modified A549 cells with hNIS gene expression and an imaging reporter 99mTc-pertechnetate (99mTcO4−) cells
have also been used to create a new orthotopic xenograft lung cancer model. Engrafting these cells to athymic nude
mice results in the development of tumors, and the level of tumor progression was measured using single proton
emission computed tomography/CT (SPECT/CT) with 99mTcO4−. This enabled the identification of tumor mass
at different time points and highlights the importance of this orthotopic xenograft model for use in monitoring
the effects of potential anticancer therapies longitudinally [27]. In order to study the cellular and molecular changes
which occur during chemically induced lung adenocarcinoma, Spella et al. developed a C57BL/6 mice model of
lung adenocarcinoma by exposing tobacco carcinogen urethane via intraperitoneal injection for 10 weeks. This
study showed that airway epithelial cell were more sensitive to KrasQ61R mutations compared to alveolar type II
cells, suggesting that tobacco-induced lung adenocarcinoma starts in airway epithelial cells [28].
Conclusion
Collectively, the analysis of genetically modified and chemically induced animal models of lung cancer has progressed
the understanding of lung cancer pathogenesis. Lung cancer in animal models progresses in a relatively short time
frame and under extremely controlled conditions and aids the identification of most relevant oncogenic pathways,
which could be novel drug targets. Understanding the genetic changes that occur during cancer progression is
complex and depends upon the type of cancer and the stimulus. There remains a lack of robust short-term, easily
reproducible, cigarette smoking-induced mouse model which replicate similar clinical features of human lung
cancer.
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